division of Genetic and Genomic Medicine
Department OF pediatrics


Abstracts Submission Deadline:
Wednesday, March 10 at
11:59 p.m. PT

SUBMIT

Open to anyone in the different specialties who work/study with rare diseases.
Join us on Friday, March 19,
1 to 5 p.m. PT

FREE Virtual Event. Registration Required.


REGISTER HERE

Abstract Submission Guidelines:
• Abstracts must be regarding any research in the field of rare disorders
• Everyone is encouraged to submit abstracts, including undergraduate and graduate students
• Abstracts should fit in one page
• Abstracts should be in Times New Roman, size 12 font, and be single spaced

The top 3 abstracts will be invited to present their work at the conference in addition to receiving a
monetary prize

– 1st place = $150, 2nd place = $100, 3rd place = $75
– Further presentation guidelines will be sent if your abstract is chosen for a talk

There will be awards for the top 3 poster presentations as well, which will be displayed online.

A sample abstract from the 2019 Rare Disorders Conference may be found
here.

Please submit a copy of your abstract directly using the link above or email a copy to Yasamin Fazeli at
yfazeli@uci.edu.


We look forward to receiving your abstracts/s



Virginia E. Kimonis, MD, MRCP,
Professor of Pediatrics, Division of Genetics and Genomic Medicine,
UCI School of Medicine


Fabiola Quintero-Rivera, MD, FACMG, Professor,
Pathology and Laboratory Medicine, Director, Laboratory of Clinical Cytogenetics and Genomics,
UCI School of Medicine


For more information, please contact program co-chair Yasamin Fazeli at yfazeli@uci.edu.

Accreditation Statement
The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The University of California, Irvine School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Full disclosure information from all those in control of content will be provided in advance.